Kymera Therapeutics Inc (NASDAQ: KYMR) closed the day trading at $40.17 up 1.72% from the previous closing price of $39.49. In other words, the price has increased by $+0.68 from its previous closing price. On the day, 612526 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a better understanding of KYMR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.73 and its Current Ratio is at 4.73. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
BofA Securities Downgraded its Buy to Neutral on January 03, 2024, whereas the target price for the stock was revised from $45 to $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 15 ’24 when Booth Bruce sold 71,764 shares for $40.46 per share. The transaction valued at 2,903,336 led to the insider holds 806,697 shares of the business.
Booth Bruce sold 55,779 shares of KYMR for $2,229,927 on Mar 14 ’24. The Director now owns 819,151 shares after completing the transaction at $39.98 per share. On Mar 13 ’24, another insider, Booth Bruce, who serves as the Director of the company, sold 139,255 shares for $42.23 each. As a result, the insider received 5,880,415 and left with 828,830 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYMR now has a Market Capitalization of 2.45B and an Enterprise Value of 2.16B. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.24 while its Price-to-Book (P/B) ratio in mrq is 5.65. Its current Enterprise Value per Revenue stands at 27.54 whereas that against EBITDA is -15.12.
Stock Price History:
Over the past 52 weeks, KYMR has reached a high of $45.31, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is 37.44, while the 200-Day Moving Average is calculated to be 24.38.
Shares Statistics:
Over the past 3-months, KYMR traded about 815.07K shares per day on average, while over the past 10 days, KYMR traded about 873.57k shares per day. A total of 55.59M shares are outstanding, with a floating share count of 54.16M. Insiders hold about 11.38% of the company’s shares, while institutions hold 90.16% stake in the company. Shares short for KYMR as of Feb 29, 2024 were 8.25M with a Short Ratio of 10.22, compared to 8.26M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.50% and a Short% of Float of 15.12%.
Earnings Estimates
Current recommendations for the stock of the company come from 12 analysts. On average, analysts expect EPS of -$0.72 for the current quarter, with a high estimate of -$0.57 and a low estimate of -$0.87, while EPS last year was -$0.7. The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.47 and low estimates of -$0.89.
Analysts are recommending an EPS of between -$1.64 and -$4.16 for the fiscal current year, implying an average EPS of -$3.07. EPS for the following year is -$3.23, with 14 analysts recommending between -$1.91 and -$4.56.
Revenue Estimates
12 analysts predict $14.83M in revenue for the current quarter. It ranges from a high estimate of $23M to a low estimate of $10M. As of the current estimate, Kymera Therapeutics Inc’s year-ago sales were $9.47M, an estimated increase of 56.70% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $12.16M, a decrease of -13.50% less than the figure of $56.70% in the same quarter last year. There is a high estimate of $26.9M for the next quarter, whereas the lowest estimate is $200k.
A total of 15 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $125M, while the lowest revenue estimate was $15.2M, resulting in an average revenue estimate of $58.68M. In the same quarter a year ago, actual revenue was $78.59M, down -25.30% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $72.78M in the next fiscal year. The high estimate is $129.1M and the low estimate is $20M. The average revenue growth estimate for next year is up 24.00% from the average revenue estimate for this year.
